Our projected milestones.
As ID4Pharma grows, we plan to grow and expand our Research and development as well. These are some of our projected milestones that we are currently on track
Some background information
2013 - ID4Pharma Launched
2014 - FIrst new drug patent was successfully licensed to Biotech company
2015 - Artificial Intelligent Chemogenomics knowledgebase Targethunter drug R&D platform
2016 - New Anti-Multiple Myeloma drug patent filed
2017 - Federal NIH Fast-Track $2.3 Million awarded to ID4Pharma for FDA IND-enabling studies of anti-multiple myeloma P62ZZ to achieve new drug status
2017-2020 - PHASE I testing - to carry out scale-up chemistry and quality control assessments of the top p62zz compounds. This aims to optimize and scale up chemistry synthesis routes for the identified compounds in order to prepare for IND-enabling preclinical studies
PHASE II - to measure in vitro potency and PK/PD oral Bioavailability of the p62zz compounds to find the efficacy and toxicity of our drug.
This aims to perform preclinical evaluations of p62zz for test of efficacy and toxicity by using human MM xenographt mouse models in comparison of the current FDA approved anti-MM drugs (e.g. bortezomib)
PHASE II (cont.)- This aims to perform preclinical evaluations of p62zz for test of efficacy and toxicity by using human MM xenographt mouse models in comparison of the current FDA approved anti-MM drugs (e.g. bortezomib).
2020 - Prepare for FDA IND
2021 - FDA Phase I trail - going for series B and C funding raised from investment companies and establishing strategic partnership with pharm/biotech companies.